DelveInsight’s, “Myocardial Infarction Pipeline Insight 2026” report provides comprehensive insights about 30+ companies and 40+ pipeline drugs in Myocardial Infarction pipeline landscape. It covers the Myocardial Infarction pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myocardial Infarction pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Myocardial Infarction Treatment Landscape @ https://www.delveinsight.com/sample-request/myocardial-infarction-pipeline-insight

Key Takeaways from the Myocardial Infarction Pipeline Report

• On May 19, 2026- Beijing Sungen Biomedical Technology Co., Ltd initiated a study is being done to see if SGC001 can be used to treat people scheduled to undergo percutaneous coronary intervention for Anterior ST-segment Elevation Myocardial Infarction. SGC001 might reduce the infarct size and inhibited inflammation, thereby preventing the incidence of major adverse cardiovascular events(MACE) events. Participants will either get SGC001 (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting SGC001 or placebo is the same. The participant was administered intravenously once. SGC001 is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe.
• On April 02, 2026- University Hospital, Caen conducted a study aims to evaluate the impact on myocardial reperfusion and residual thrombotic burden of adding Cangrelor -a potent and immediate P2Y12 inhibitor- to ticagrelor in primary PCI patients with high on ticagrelor platelet reactivity compared to standard of care with ticagrelor alone.
• DelveInsight’s Myocardial Infarction pipeline report depicts a robust space with 30+ active players working to develop 40+ pipeline therapies for Myocardial Infarction treatment.
• The leading Myocardial Infarction Companies such as Novo Nordisk, CeleCor Therapeutics, Bayer, Shanghai Zhongshan Hospital, Takeda Pharmaceuticals, Nexel, Moleac Pte Ltd., LIB Therapeutics, Windtree Therapeutics, Faraday Pharmaceuticals, CSL Behring, Cardior Pharmaceuticals, AstraZeneca, R-Pharma, Shilpa Biologicals and others.
• Promising Myocardial Infarction Pipeline Therapies such as Ilomedin, MiSaver®, BI 765845, Empagliflozin, Tenecteplase, Clopidogrel, Enoxaparin, Eplerenone, and others.

Download for updates and be a part of the revolution in Cardiovascular Diseases Care @ Myocardial Infarction Clinical Trials Assessment

The Myocardial Infarction Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Myocardial Infarction Pipeline Report also highlights the unmet needs with respect to the Myocardial Infarction.

Myocardial Infarction Overview

A myocardial infarction, commonly known as a heart attack, is the irreversible necrosis of heart muscle due to prolonged ischemia, usually caused by a blockage in the arteries that supply blood to the heart. If a healthcare provider doesn’t restore blood flow quickly, a heart attack can cause permanent heart damage and death. The lack of blood flow can occur because of many different factors but is usually related to a blockage in one or more of the coronary arteries. Treatment for a heart attack aims to restore blood flow to the affected heart muscle as soon as possible, and it can involve various methods, such as medication, percutaneous coronary intervention (PCI), and coronary artery bypass grafting. Several key factors affect the risk of having a heart attack, including family history, high blood pressure, high cholesterol, and smoking.

Myocardial Infarction Emerging Drugs Profile

• FDY 5301: Faraday Pharmaceuticals

FDY-5301 is an elemental reducing agent containing sodium iodide for which Faraday has obtained method of use patent protection in major markets worldwide. Faraday has selected FDY-5301 for investigation in the belief that its properties are uniquely well-suited to mitigate ischemia-reperfusion injury (IRI). In preclinical IRI models, FDY-5301 reduced tissue damage, infarct size, and inflammation. FDY-5301 functions as a catalytic neutralizer of hydrogen peroxide, a prominent reactive oxygen species implicated in the IRI cascade leading to cardiomyocyte death, and also acts as an immunomodulating agent. Currently, the drug is in Phase III stage of its clinical trial for the treatment AMI.

• Glenzocimab: Acticor Biotech

Glenzocimab is a humanized monoclonal antibody fragment designed to target the human platelet glycoprotein VI (GPVI), which plays a crucial role in thrombus formation and stability. Its mechanism of action involves inhibiting platelet activation and aggregation, particularly in the context of ischemic stroke and myocardial infarction. Currently, it is in Phase II stage of its clinical trial for the treatment of myocardial infarction.

• BI765845: Boehringer Ingelheim

BI765845 is an experimental drug developed by Boehringer Ingelheim, classified as an anti-ischemic agent. It aims to address ischemic conditions by improving oxygen supply and reducing oxygen demand in affected tissues. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Myocardial infarction.

Learn more about Myocardial Infarction Drugs opportunities in our groundbreaking Myocardial Infarction research and development projects @ Myocardial Infarction Unmet Needs

The Myocardial Infarction Pipeline Report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Myocardial Infarction with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myocardial Infarction Treatment.
• Myocardial Infarction Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Myocardial Infarction Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myocardial Infarction market.

Myocardial Infarction Companies

Novo Nordisk, CeleCor Therapeutics, Bayer, Shanghai Zhongshan Hospital, Takeda Pharmaceuticals, Nexel, Moleac Pte Ltd., LIB Therapeutics, Windtree Therapeutics, Faraday Pharmaceuticals, CSL Behring, Cardior Pharmaceuticals, AstraZeneca, R-Pharma, Shilpa Biologicals and others.

Myocardial Infarction pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Myocardial Infarction Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Stay informed about how we’re transforming the future of Cardiovascular Diseases @ Myocardial Infarction Market Drivers and Barriers, and Future Perspectives

Scope of the Myocardial Infarction Pipeline Report

• Coverage- Global
• Myocardial Infarction Companies- Novo Nordisk, CeleCor Therapeutics, Bayer, Shanghai Zhongshan Hospital, Takeda Pharmaceuticals, Nexel, Moleac Pte Ltd., LIB Therapeutics, Windtree Therapeutics, Faraday Pharmaceuticals, CSL Behring, Cardior Pharmaceuticals, AstraZeneca, R-Pharma, Shilpa Biologicals and others.
• Myocardial Infarction Pipeline Therapies- Ilomedin, MiSaver®, BI 765845, Empagliflozin, Tenecteplase, Clopidogrel, Enoxaparin, Eplerenone, and others.
• Myocardial Infarction Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Myocardial Infarction Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Myocardial Infarction Pipeline on our website @ Myocardial Infarction Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Myocardial Infarction: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Myocardial Infarction – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. FDY 5301: Faraday Pharmaceuticals
9. Mid Stage Products (Phase II)
10. Glenzocimab: Acticor Biotech
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. Drug Name: Company Name
14. Mid Stage Products (Phase II)
15. Preclinical Stage Products
16. Drug Name: Company Name
17. Inactive Products
18. Myocardial Infarction – Collaborations Assessment- Licensing / Partnering / Funding
19. Myocardial Infarction – Unmet Needs
20. Myocardial Infarction – Market Drivers and Barriers
21. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/myocardial-infarction-pipeline-insight